Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis

по Purohit, Vivek, Riley, Steve, Tan, Huaming, Ports, William C.
Опубликовано в: J Clin Pharmacol (2020)

Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data

по Armstrong, April W., Koning, J. Will, Rowse, Simon, Tan, Huaming, Mamolo, Carla, Kaur, Mandeep
Опубликовано в: Dermatol Ther (Heidelb) (2016)

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

по Xin, Xiaoyan, Zeng, Xianqin, Gu, Huajian, Li, Min, Tan, Huaming, Jin, Zhishan, Hua, Teng, Shi, Rui, Wang, Hongbo
Опубликовано в: Sci Rep (2016)

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

по Valenzuela, Fernando, Papp, Kim A, Pariser, David, Tyring, Stephen K, Wolk, Robert, Buonanno, Marjorie, Wang, Jeff, Tan, Huaming, Valdez, Hernan
Опубликовано в: BMC Dermatol (2015)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposu...

по Burmester, Gerd R, Nash, Peter, Sands, Bruce E, Papp, Kim, Stockert, Lori, Jones, Thomas V, Tan, Huaming, Madsen, Ann, Valdez, Hernan, Cohen, Stanley B
Опубликовано в: RMD Open (2021)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups

по Callender, Valerie D., Alexis, Andrew F., Stein Gold, Linda F., Lebwohl, Mark G., Paller, Amy S., Desai, Seemal R., Tan, Huaming, Ports, William C., Zielinski, Michael A., Tallman, Anna M.
Опубликовано в: Am J Clin Dermatol (2019)